News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors
Clinical Forum Insights

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Clinical Forum Insights
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

HELEN W. BOUCHER, MD

Advertisement

Articles by HELEN W. BOUCHER, MD

Implications of the 21st Century Cures Act on Antibiotic Drug Development

ByALLISON KOMIRENKO, PHARMD,CAROLINE T. STORK, PHD,JOHN MOHR, PHARMD,HELEN W. BOUCHER, MD
May 8th 2017

Experts weigh in on what Congress is doing to tackle the threat of antibiotic resistance.

Advertisement

Latest Updated Articles

  • Implications of the 21st Century Cures Act on Antibiotic Drug Development
    Implications of the 21st Century Cures Act on Antibiotic Drug Development

    Published: May 8th 2017 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

FDA Clears First At-Home Diagnostic for RSV, Influenza, and COVID-19 in Adults, Young Infants

2

CDC ACIP Workgroup Reviewing FDA-Approved HPV Vaccines

3

Assessing Social Determinants of Health with Treatment Failure In UTIs

4

Antifungal Earns FDA QIDP and Fast Track Designations Amid Rising Antifungal Resistance

5

UTI Treatment: Tailoring Patient Education and the Role of Insurance Payers

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us